{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:23:31Z","timestamp":1760081011261,"version":"3.40.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03775-z","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:53:40Z","timestamp":1730822020000},"page":"2761-2767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab"],"prefix":"10.1007","volume":"27","author":[{"given":"Christina","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Maarup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Skovgaard","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikte","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-5173","authenticated-orcid":false,"given":"Nicholas","family":"Willumsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"10","key":"3775_CR1","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, et al. Epidemiology of glioblastoma multiforme-literature review. Cancers (Basel). 2022;14(10):2412. https:\/\/doi.org\/10.3390\/cancers14102412.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3775_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"issue":"9","key":"3775_CR3","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3390\/cells10092257","volume":"10","author":"M Dapash","year":"2021","unstructured":"Dapash M, Hou D, Castro B, Lee-Chang C, Lesniak MS. The interplay between glioblastoma and its microenvironment. Cells. 2021;10(9):2257. https:\/\/doi.org\/10.3390\/cells10092257.","journal-title":"Cells"},{"issue":"10","key":"3775_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/1541-7786.MCR-13-0236","volume":"11","author":"LS Payne","year":"2013","unstructured":"Payne LS, Huang PH. The pathobiology of collagens in glioma. Mol Cancer Res. 2013;11(10):1129\u201340. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0236.","journal-title":"Mol Cancer Res"},{"key":"3775_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.812916","author":"S Jain","year":"2022","unstructured":"Jain S, Chalif EJ, Aghi MK. Interactions between anti-angiogenic therapy and immunotherapy in glioblastoma. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2021.812916.","journal-title":"Front Oncol"},{"issue":"6","key":"3775_CR6","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/cam4.3732","volume":"10","author":"JL Parker","year":"2021","unstructured":"Parker JL, Kuzulugil SS, Pereverzev K, et al. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis. Cancer Med. 2021;10(6):1955\u201363. https:\/\/doi.org\/10.1002\/cam4.3732.","journal-title":"Cancer Med"},{"issue":"3","key":"3775_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41416-019-0603-6","volume":"122","author":"J M\u00fcller Bark","year":"2020","unstructured":"M\u00fcller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020;122(3):295\u2013305. https:\/\/doi.org\/10.1038\/s41416-019-0603-6.","journal-title":"Br J Cancer"},{"issue":"1","key":"3775_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02133-z","volume":"40","author":"C Jensen","year":"2021","unstructured":"Jensen C, Nissen NI, Von Arenstorff CS, Karsdal MA, Willumsen N. Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. J Exp Clin Cancer Res. 2021;40(1):1\u201311. https:\/\/doi.org\/10.1186\/s13046-021-02133-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"3775_CR9","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/cancers15061879","volume":"15","author":"S Marino","year":"2023","unstructured":"Marino S, Menna G, Di Bonaventura R, et al. The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment\u2014a systematic review. Cancers (Basel). 2023;15(6):1879. https:\/\/doi.org\/10.3390\/cancers15061879.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3775_CR10","first-page":"3742","volume":"11","author":"E Mohiuddin","year":"2021","unstructured":"Mohiuddin E, Wakimoto H. Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches. Am J Cancer Res. 2021;11(8):3742\u201354.","journal-title":"Am J Cancer Res"},{"key":"3775_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061879","author":"S Marino","year":"2023","unstructured":"Marino S, Menna G, Di Bonaventura R, et al. The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment\u2014a systematic review. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15061879.","journal-title":"Cancers"},{"issue":"8","key":"3775_CR12","doi-asserted-by":"publisher","first-page":"7049","DOI":"10.3390\/ijms24087049","volume":"24","author":"A Soles","year":"2023","unstructured":"Soles A, Selimovic A, Sbrocco K, et al. Extracellular matrix regulation in physiology and in brain disease. Int J Mol Sci. 2023;24(8):7049. https:\/\/doi.org\/10.3390\/ijms24087049.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"3775_CR13","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.3390\/cancers14215386","volume":"14","author":"R Hedna","year":"2022","unstructured":"Hedna R, Kovacic H, Pagano A, et al. Tau protein as therapeutic target for cancer? Focus on glioblastoma. Cancers (Basel). 2022;14(21):5386. https:\/\/doi.org\/10.3390\/cancers14215386.","journal-title":"Cancers (Basel)"},{"key":"3775_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1126\/scitranslmed.aax1501","volume":"12","author":"R Gargini","year":"2020","unstructured":"Gargini R, Segura-Collar B, Herr\u00e1nz B, et al. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Sci Transl Med. 2020;12:527. https:\/\/doi.org\/10.1126\/scitranslmed.aax1501.","journal-title":"Sci Transl Med."},{"key":"3775_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fneur.2015.00090","volume":"6","author":"D Inekci","year":"2015","unstructured":"Inekci D, Jonesco DS, Kennard S, Karsdal MA, Henriksen K. The Potential of pathological protein fragmentation in blood-based biomarker development for dementia \u00e2\u20ac\u201c with emphasis on Alzheimer\u00e2\u20acTMs disease. Front Neurol. 2015;6:8. https:\/\/doi.org\/10.3389\/fneur.2015.00090.","journal-title":"Front Neurol"},{"issue":"4","key":"3775_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3233\/JAD-140984","volume":"43","author":"K Henriksen","year":"2014","unstructured":"Henriksen K, Byrjalsen I, Christiansen C, Karsdal MA. Relationship between serum levels of tau fragments and clinical progression of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2014;43(4):1331\u201341. https:\/\/doi.org\/10.3233\/JAD-140984.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"5","key":"3775_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064990","volume":"8","author":"K Henriksen","year":"2013","unstructured":"Henriksen K, Wang Y, S\u00f8rensen MG, et al. An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function. PLoS ONE. 2013;8(5): e64990. https:\/\/doi.org\/10.1371\/journal.pone.0064990.","journal-title":"PLoS ONE"},{"issue":"10","key":"3775_CR18","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3390\/cancers12102786","volume":"12","author":"C Jensen","year":"2020","unstructured":"Jensen C, Sinkeviciute D, Madsen DH, et al. Granzyme B degraded type IV collagen products in serum identify melanoma patients responding to immune checkpoint blockade. Cancers (Basel). 2020;12(10):2786. https:\/\/doi.org\/10.3390\/cancers12102786.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"3775_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084934","volume":"8","author":"JM Sand","year":"2013","unstructured":"Sand JM, Larsen L, Hogaboam C, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis\u2014validation of two novel biomarker assays. PLoS ONE. 2013;8(12): e84934. https:\/\/doi.org\/10.1371\/journal.pone.0084934.","journal-title":"PLoS ONE"},{"issue":"6","key":"3775_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/neuonc\/noab196.214","volume":"23","author":"S Maarup","year":"2021","unstructured":"Maarup S, Skadborg S, Borch A, et al. CTIM-22. Nivolumab and bevacizumab for recurrent glioblastoma; t-cell reactivity against autologous tumor cells. Neuro Oncol. 2021;23(6):54\u20135. https:\/\/doi.org\/10.1093\/neuonc\/noab196.214.","journal-title":"Neuro Oncol"},{"key":"3775_CR21","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6896","author":"S Zaman","year":"2018","unstructured":"Zaman S, Chobrutskiy BC, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma. Oncol Rep. 2018. https:\/\/doi.org\/10.3892\/or.2018.6896.","journal-title":"Oncol Rep"},{"issue":"22","key":"3775_CR22","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.3390\/cancers13225818","volume":"13","author":"A Pagano","year":"2021","unstructured":"Pagano A, Breuzard G, Parat F, et al. Tau regulates glioblastoma progression, 3D cell organization, growth and migration via the PI3K-AKT Axis. Cancers (Basel). 2021;13(22):5818. https:\/\/doi.org\/10.3390\/cancers13225818.","journal-title":"Cancers (Basel)"},{"key":"3775_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7554\/eLife.62927","volume":"10","author":"MIP Ramos","year":"2021","unstructured":"Ramos MIP, Tian L, de Ruiter EJ, et al. Cancer immunotherapy by nc410, a lair-2 fc protein blocking human lair-collagen interaction. Elife. 2021;10:8. https:\/\/doi.org\/10.7554\/eLife.62927.","journal-title":"Elife"},{"issue":"1\u20132","key":"3775_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2013.08.013","volume":"264","author":"J Kmiecik","year":"2013","unstructured":"Kmiecik J, Poli A, Brons NHC, et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013;264(1\u20132):71\u201383. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.08.013.","journal-title":"J Neuroimmunol"},{"key":"3775_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fimmu.2020.00205","volume":"11","author":"M Mohme","year":"2020","unstructured":"Mohme M, Neidert MC. Tumor-specific T cell activation in malignant brain tumors. Front Immunol. 2020;11:8. https:\/\/doi.org\/10.3389\/fimmu.2020.00205.","journal-title":"Front Immunol"},{"issue":"1","key":"3775_CR26","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","volume":"12","author":"AH Lee","year":"2021","unstructured":"Lee AH, Sun L, Mochizuki AY, et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021;12(1):6938. https:\/\/doi.org\/10.1038\/s41467-021-26940-2.","journal-title":"Nat Commun"},{"issue":"1","key":"3775_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","volume":"27","author":"J Bryan Iorgulescu","year":"2021","unstructured":"Bryan Iorgulescu J, Gokhale PC, Speranza MC, et al. Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin Cancer Res. 2021;27(1):276\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2291.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3775_CR28","doi-asserted-by":"publisher","first-page":"19761","DOI":"10.1038\/s41598-019-56268-3","volume":"9","author":"N Willumsen","year":"2019","unstructured":"Willumsen N, Ali SM, Leitzel K, et al. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Sci Rep. 2019;9(1):19761. https:\/\/doi.org\/10.1038\/s41598-019-56268-3.","journal-title":"Sci Rep"},{"issue":"1","key":"3775_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s40425-018-0474-z","volume":"6","author":"C Jensen","year":"2018","unstructured":"Jensen C, Madsen DH, Hansen M, et al. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. J Immunother Cancer. 2018;6(1):152. https:\/\/doi.org\/10.1186\/s40425-018-0474-z.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3775_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3340\/jkns.2012.51.3.147","volume":"51","author":"YJ Seo","year":"2012","unstructured":"Seo YJ, Cho WH, Kang DW, Cha SH. Extraneural metastasis of glioblastoma multiforme presenting as an unusual neck mass. J Korean Neurosurg Soc. 2012;51(3):147. https:\/\/doi.org\/10.3340\/jkns.2012.51.3.147.","journal-title":"J Korean Neurosurg Soc"},{"key":"3775_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/CANCERS16172975","volume":"16","author":"MA Rahman","year":"2024","unstructured":"Rahman MA, Ali MM. Recent treatment strategies and molecular pathways in resistance mechanisms of antiangiogenic therapies in glioblastoma. Cancers. 2024;16:17. https:\/\/doi.org\/10.3390\/CANCERS16172975.","journal-title":"Cancers"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:17:03Z","timestamp":1747405023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["3775"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03775-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MK, NW and CJ are employed at Nordic Bioscience A\/S. MK and NW own stocks at Nordic Bioscience A\/S. IMS has received honoraria from Novartis, Roche, Merck, and Bristol-Myers Squibb; a restricted research grant from Novartis; and financial support for attending symposia from Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}